100
Participants
Start Date
April 30, 2014
Primary Completion Date
April 30, 2030
Study Completion Date
April 30, 2030
Bevacizumab
10mg/kg, intravenous (iv), biweekly, 1 year
Thalidomide
3mg/kg, oral, daily, 1 year
Celecoxib
50-400mg, oral bid, daily, 1 year
Fenofibric acid
90mg/m2, oral, daily, 1 year
Etoposide
35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
Cyclophosphamide
2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
Etoposide phosphate
0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
Cytarabine
16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
RECRUITING
Medical University of Vienna, Vienna
RECRUITING
University hospital Rigshospitalet, Copenhagen
RECRUITING
Kepler Universitätsklinikum Med Campus IV, Linz
RECRUITING
Salzburger Universitätsklinikum, Salzburg
RECRUITING
Onkologisk-hematologisk seksjon Barneklinikken Haukeland universitetssjukehus, Bergen
RECRUITING
Medical University of Innsbruck, Innsbruck
RECRUITING
Medical University of Graz, Graz
RECRUITING
Motol University Hospital Prague, Prague
RECRUITING
Hospital Infantil Universitario Nino Jesus, Madrid
RECRUITING
Helen DeVos Children's Hospital, Grand Rapids
TERMINATED
Centre Oscar Lambret, Lille
RECRUITING
University Hospital Brno, Brno
RECRUITING
Centre Léon Bérard, Lyon
RECRUITING
Dell Children's Medical Group SFC-HEM/ONC, Austin
TERMINATED
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
TERMINATED
Dana-Farber Cancer Institute and Boston Children's Hospital, Boston
RECRUITING
Sahlgrenska Universitetssjukhuset, Gothenburg
RECRUITING
Universitetssjukhuset Linköping, Linköping
RECRUITING
Skånes universitetssjukhus, Lund
RECRUITING
Karolinska University Hospital, Stockholm
RECRUITING
Norrlands Universitetssjukhus, Umeå
RECRUITING
Akademiska sjukhuset, Uppsala
Medical University of Vienna
OTHER